Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment
Luxa Biotechnology has been awarded a $4 million grant from the California Institute for Regeneration Medicine, supporting its ongoing Phase 1/2a clinical study of the RPESC-RPE-4W cell transplantation for the treatment of dry age-related macular degeneration (AMD).
The RPESC-RPE-4W, a cutting-edge therapy developed from adult retinal pigment epithelial stem cells, aims to replace deteriorated retinal cells and offers the potential to significantly restore vision in patients affected by dry AMD.
Original articles
